,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,breast,4', 'breast', 'trastuzumab', 'destiny-breast04']
#asco22 news: destiny-breast04 practice changing for her2-low metastatic breast cancer. read our report of the trastuzumab deruxtecan study presented by shanu modi of , with comments from and patricia lorusso 
Medicine Matters #oncology publishes the latest news, commentary, research, and educational resources in a range of topics across oncology.